Feeds:
Posts
Comments

Posts Tagged ‘Novartis’

new drugI imagine we’ve all been closely following the Ebola outbreak in Africa. Although we’re a long way from the finish line, how encouraging is it that a very experimental biotech drug may be saving the lives of a couple of infected healthcare workers.

Moving toward the integrated  display of a glucose monitoring system, and insulin pump system for diabetes (Dexcom and Insulet).

Will animal testing eventually go the way of the dodo bird in drug development? Maybe – now that scientists are developing “human body on a chip” technology. Fascinating stuff.

Big investment money going after CARTs (leading-edge cancer treatment based on re-engineering the patient’s own white blood cells).

Alliance between BMS and Allied Minds to speed R&D developments in university research insititutions (data-, expertise-, and resource-sharing).

Novartis on the threshold of a new chronic heart failure treatment.

BONUS: will there soon be a blood test to detect ANY type of cancer?

Read Full Post »

Here is a listing of recent pharma/device/biotech job openings in training, for those who are interested:

Manager, Sales Training and Development, Sunovion, MA

Sales Training Manager – Oncology, EMD Serono, MA

Manager/Associate Director, Oncology Clinical Training & Development, Novartis, NJ

Manager/Associate Director, Sales Training (Oncology), Novartis, NJ

Sales Training Manager, Shionogi, NJ

Hospital & Specialty Sales Trainer, Daiichi-Sankyo, NJ

National Sales Trainer, Daiichi-Sankyo, NJ

Director, Talent Management, Daiichi-Sankyo, NJ

Senior Manager, Leadership Development, Daiichi-Sankyo, NJ

Manager, Medical Device Training and Communications, Ikaria, NJ

Sales Training Manager – Oncology, Astellas, IL

Sr. Manager, Training & Communication (Compliance), Abbott, IL

Manager of Sales Training, Vivus, CA

Manager/Sr. Manager, Learning Technologies, Roche/Genentech, CA

Note: Impactiviti has no connection to the hiring personnel in these companies. The links are posted strictly as a service. Apply directly to the companies according to directions given on their individual job postings.

_________

Impactiviti is the Pharmaceutical Connection Agency. As the eHarmony of sales/training/marketing, we help our pharma/biotech clients find optimal outsource vendors through our unique trusted referral network. Need something? Ask Steve.

Learn more about us here.

 

Read Full Post »

*****

Impactiviti Daily will not be published next week, as I will be attending the annual Society of Pharmaceutical and Biotech Trainers conference (SPBT) in Orlando.

TODAY’S NEWS:

As the pre-ASCO news heats up, the big headline will be leukemia treatments – specifically, BMS‘ Sprycel and Novartis‘ Gleevec and Tasigna (just inTasigna shown superior to Gleevec in slowing CML: 18-month results). Treatments in this class, by the way, are something near miracle drugs. They’ve totally revolutionized blood cancer treatments. In related news, Novartis’ Afinitor (approved for kidney cancer) meets goals in a trial for pancreatic cancer.

Why should you be interested in a “nanosponge”? Well, there’s this – Scientists have found that a delivery system based on a technique called nanosponge is three to five times more effective at reducing tumor growth than direct injectionmore

Will Amgen‘s new osteoporosis drug Prolia find its true home in oncology treatment? – The company has also applied for FDA approval to market the drug to breast cancer and prostate cancer patients who are undergoing a hormone treatment that weakens their bones. What’s more, the company is conducting tests designed to show that Prolia prevents cancer from spreading to the bones — an indication that could push sales of the drug to as much as $6 billion annually, some analysts predictmore Also – huge sales force push for Prolia.

20% of high school students abuse prescription drugs. Wow – sobering.

RECOMMENDED

Simulations/Gaming. Live training simulations, digital sims (eLearning) and on-line games – our partner network has the expertise you need.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

How to reduce e-mail ping-pong. You know all that back-and-forth? Here’s a way to undercut it at the start!

JUST FOR FUN

See-through animals. Ten of them. Amazing.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

COMING UP SOON: BDI’s Social Communications and Healthcare half-day gathering. NYC, May 11 – all details here. I will be leading a roundtable. Use discount code IMPACT for $155 registration rate.

*****

TODAY’S NEWS

Allergan – Rolling high-stakes legal dice re: Botox. Here and here.

Novo’s Victoza: nice results in comparison with Merck‘s Januvia. Plus, an experimental Januvia competitor gets dropped by Forest Labs.

Experimental once-a-day malaria drug looking really good – An experimental once-a-day malaria drug worked as well at treating the mosquito-borne illness as Novartis AG’s twice-daily pill Coartem, according to a study published today in the journal Lancetmore

RECOMMENDED

Account Management Training – Need to make your account managers more effective? Creative and successful programs are available from Impactiviti’s partner network.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Surround Yourself with Smart People.

JUST FOR FUN

Serene Sunrises. 40. A visual treat.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS

Novartis announces a major US reorganization, including re-aligned business units, and cuts. Ouch.

Crystal ball – what will be the biggest drug(s) in 2014? Here are some educated guesses.

Use Remicade early in Crohn’s, the results say – “The results are pretty definitive,” Sandborn told MedPage Today. “Most patients should receive infliximab combination therapy as the most effective strategy.“…more

Genzyme‘s Campath for MS:  preliminary data look quite promising – Data presented on Wednesday at the annual meeting of the American Academy of Neurology showed that after four years, 71 percent of patients had no relapse or worsening of disability. That compares with 35 percent for patients taking Rebif, a rival drug made by EMD Serono, an affiliate of Germany’s Merck KGaA and Pfizer Incmore

RECOMMENDED

ANY Pharma sales training – The Impactiviti Partner Network is your resource if you’re looking for a great training provider. We “matchmake” best-in-class partners to meet your training needs – at no cost to you!  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

I’m Restless – how about you?

JUST FOR FUN

Come out of your shell. Cool photos – just trust me and look.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS

Hugely encouraging results for Novartis‘ new experimental (oral) MS treatment – Novartis’ Gilena has delivered an impressive performance in a Phase III trial in patients multiple sclerosis, cutting relapse rates by 62% in treatment-naïve patients and sustaining its effects for more than two years. Importantly, data from the two-year FREEDOMS study, presented at the American Academy of Neurology annual meeting, also showed that relapse rates were reduced by a significant 44% in patients who had previously been treated with other drugs for MS, highlighting the potential benefit of switching therapiesmore

Gilead starts late stage testing of “4-in-1” HIV pill.

An interesting account of regulatory “unintended consequences.” How to make a cheap drug very expensive.

Cephalon hopes to gain more cheddar by adding some Swiss. Sorry – couldn’t resist…

Celgene: the new “big kid” on the block.

RECOMMENDED

Coaching Skills – The Impactiviti Partner Network is your resource if you’re looking to improve the coaching skills of your employees.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

An amusing patient health video made by J&J. Well worth 4 minutes of your time. The Appointment.

JUST FOR FUN

Oldie but goodie from The Onion – American to start charging fees to Non-passengers.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

Coming up on May 11th: BDI’s Social Communications & Healthcare event – half day session in NYC with Case Studies and Roundtables (I’ll be leading one of the roundtables). Top speakers from J&J, Pfizer, and more! These are always great networking and learning events. Hope to see you there!

For more information, including registration, please click here to visit the event website. Use promo code IMPACT for a discounted rate of $155.

TODAY’S NEWS

In Celgene‘s pipeline – a promising oral RA (Rheumatoid Arthritis) treatment – Celgene Corp. believes sales of lead development candidate Apremilast will be $2 billion to $3 billion a year in psoriasis and psoriatic arthritis. The drug, which would compete with some of the world’s biggest selling therapies, is expected to enter late-stage trials this year and could be launched in 2014 or 2015, the company said. The projection came during the Summit, N.J., drug maker’s research and development presentation in New York Thursdaymore But, not such good news about low-dose aspirin as a RA preventative.

Oh, by the way – there were a few suicides, too. How not to get approval for Daxas (Forest Labs).

The arguments begin the Novartis discrimination lawsuit. How many isolated incidents indicate a systemic problem? This one’s going to get sticky…

Letting Go. A challenge to think differently.

RECOMMENDED

Diversity/Ethics training– We can recommend best-in-class partners and programs for your needs.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

“Compulsive Generosity” due to Parkinson’s Rx – an embezzler gets off with an imaginative “the drug made me do it” plea. Ludicrous.

JUST FOR FUN

The Enlightened Stupid Marketer. 3 1/2 minutes of fun with Kevin Nalts.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

Older Posts »